The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

Other

The United States of America As Represented by the Secretary of

The Penn State Research Foundation

Nestec S.a.

Gentest Corporation

Frank J Gonzalez

Harry V Gelboin

Kristopher W Krausz

Curtis C Harris

Pedro Fernandez-Salguero

Andrew D Patterson

Andrea M Pfeifer

Bernard Moss

James B Mitchell

Fei Li

Cen Xie

Changtao Jiang

Soumen Manna

Ewy Mathe

Majda Haznadar

Narayana Battula

Katharine C Mace

Shantu G Amin

Dhimant H Desai

Bruce W Penman

James P Hardwick

Jeffrey R Idle

Charles L Chrespi

Talia Sher

Urs A Meyer

Soumen K Manna

Tian J Yang

Dhimant Desai

Shantu Amin

Curtis Craig Harris

Soumen Mann

Soumen Kanti Manna

The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

Method for the diagnosis and prognosis of cancer

Disclosed is an apparatus to reduce the amount of time required to assemble an array of construction reinforcing bars wherein a consistent gap is present between the reinforcing bars and the height of the exposed end of the reinforcing bars is substantially identical while simultaneously covering the exposed ends of the reinforcing bars to prevent injuries to nearby individuals that may come into contact with the exposed ends of the reinforcing bars.

Apparatus to position reinforcing bars and prevent injury

Compositions and methods for the diagnosis, treatment, and prevention of neoplasia (e.g., colorectal cancer).

Compositions and methods for detecting neoplasia

The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R, R, R, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal. 

Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R, R, R, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least Cone compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal. 

Inhibitors of the farnesoid X receptor and uses in medicine

The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.

Agents that bind to and inhibit human cytochrome P450 2C19

The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.

Antibodies that bind to and inhibit human cytochrome P450 2C9*1, 2C9*2, and 2C9*3

The present invention provides compositions, methods, and kits for the detection of genetic polymorphisms or mutations of the dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphisms or mutations generally occur in the dihydropyrimidine dehydrogenase (DPD) gene in chromosome 1. Also provided are mutant forms of DPD.

Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations

The present invention provides compositions, methods and kits for the detection of genetic polymorphisms or mutations related to dihydropyrimidine dehydrogenase deficiency (DPDD). The polymorphism or mutations generally occur in the dihydropyrimidine dehydrogenase DPD gene in chromosome 1. Also provided are mutant forms of DPD.

The invention provides monoclonal antibodies to human cytochrome P450 2C8, 2C9, 2C18, and 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of the various human cytochrome P450 2C family members and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C family members, and in methods of screening individuals for a poor metabolizing individual human P450 2C family phenotypes.

Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19

The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 1A2 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 1A2 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 1A2, and in methods of measuring p450 1A2 levels in individuals relative to p450 1A2 levels in a control population.

Agents that bind to and inhibit human cytochrome P450 1A2

The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2A6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2A6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in an individual relative to p450 2A6 levels in a control population.

Growing community of inventors

Bethesda, MD, United States of America

Frank J Gonzalez